(02) 9850 4000
GlyTherix
  • Home
  • Company
  • Product Pipeline
  • For Investors
  • News
  • Contact Us
Select Page
GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

by GlyTherix | Jul 16, 2020

16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
Four New Peer Reviewed Papers Underline the Strength of the GlyTherix  Technology

Four New Peer Reviewed Papers Underline the Strength of the GlyTherix Technology

by GlyTherix | May 19, 2020

Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer

ASCO meeting abstract: Glypican-1 as a novel immunotherapeutic target in prostate cancer

by GlyTherix | Feb 14, 2018

Facebook Twitter Google+ LinkedIn A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic’s head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary...

MORE INFO

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

Recent Posts

  • GlyTherix is a recipient of the first round of the TIA pipeline accelerator 2020-21 scheme
  • Carina Biotech and GlyTherix enter into CAR-T partnership
  • Glytherix seeks AUD 7M Series A funding after securing grant – CEO

RECENT POSTS

  • GlyTherix is a recipient of the first round of the TIA pipeline accelerator 2020-21 scheme
  • Carina Biotech and GlyTherix enter into CAR-T partnership
  • Glytherix seeks AUD 7M Series A funding after securing grant – CEO
  • GlyTherix Awarded $3 Million Co-operative Research Centre Project Grant

ENQUIRIES

Address
Suite 2, Ground Floor, 
75 Talavera Road, 
Macquarie Park, NSW 2113, 
Australia

Phone
Intl: +612 9850 4000
Aust: 02 9850 4000
(Compare your time zone with Sydney here)

MORE INFO

Would you like to talk with Glytherix about:

  • Investing in us?
  • Partnering with us?
  • Media events?
  • Some feedback?
  • Home
  • News
  • Terms of Use
  • Privacy Policy
  • Contact Us

COPYRIGHT 2021 | GLYTHERIX - ALL RIGHTS RESERVED